FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by Eastern Cooperative Oncology Group.
Recruitment status was  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
Eastern Cooperative Oncology Group Identifier:
First received: March 3, 2005
Last updated: March 8, 2012
Last verified: June 2006

March 3, 2005
March 8, 2012
January 2005
August 2006   (final data collection date for primary outcome measure)
  • Response rate [ Designated as safety issue: No ]
  • Progression-free and overall survival [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00104884 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma

RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable stage III or stage IV malignant melanoma.



  • Determine the response rate in patients with unresectable stage III or stage IV malignant melanoma treated with FR901228 (depsipeptide).


  • Determine the progression-free and overall survival of patients treated with this drug.
  • Determine the toxicity profile of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years.

PROJECTED ACCRUAL: A total of 22-40 patients will be accrued for this study within 18 months.

Phase 2
Masking: Open Label
Primary Purpose: Treatment
  • Intraocular Melanoma
  • Melanoma (Skin)
Drug: romidepsin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
Not Provided
August 2006   (final data collection date for primary outcome measure)


  • Diagnosis of malignant melanoma meeting 1 of the following stage criteria:

    • Unresectable stage III disease
    • Stage IV disease
  • The following melanoma types are allowed:

    • Cutaneous
    • Mucosal
    • Ocular
    • Unknown primary
  • Measurable disease by physical examination or imaging studies

    • Lesions on bone scan and positron-emission tomography are not considered measurable
    • Measurable disease must be outside a previously irradiated port
  • Palpable cutaneous or nodal metastases suitable for punch, trucut, or similar biopsy
  • No active CNS metastases by brain CT scan or MRI (performed < 4 weeks before study entry)

    • Solitary CNS lesions treated with surgery or stereotactic radiosurgery/gamma knife are allowed provided disease has been stable AND there is no evidence of new CNS lesions within the past 3 months



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • WBC ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL


  • AST and/or ALT ≤ 2.5 times upper limit of normal
  • Bilirubin normal


  • Creatinine normal OR
  • Creatinine clearance ≥ 60 mL/min


  • No history of coronary atherosclerotic heart disease
  • No history of myocardial infarction
  • No history of congestive heart failure
  • EKG normal
  • LVEF > 40% by MUGA
  • QTc < 500 msec
  • No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
  • Cardiac hypertrophy allowed

    • No left ventricular hypertrophy by EKG


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Potassium ≥ 4.0 mmol/L
  • Magnesium ≥ 2 mg/dL
  • No nonmelanoma malignancy within the past 5 years except carcinoma in situ or squamous cell or basal cell skin cancer
  • No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study compliance
  • No other uncontrolled illness
  • No other condition that would preclude study participation


Biologic therapy

  • At least 4 weeks since prior immunotherapy, including any of the following:

    • Interferon
    • Interleukin
    • Sargramostim (GM-CSF)
    • Vaccines
  • No concurrent biologic agents except filgrastim (G-CSF)


  • No prior FR901228 (depsipeptide)
  • No prior chemotherapy
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • Prior whole brain radiotherapy allowed
  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • See Disease Characteristics
  • No prior coronary artery bypass graft or stent


  • At least 5 half-lives since prior and no concurrent agents that may cause QTc prolongation
  • No other concurrent investigational agents
  • No other concurrent antineoplastic agents
  • No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g., sodium valproate)
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent hydrochlorothiazide
18 Years and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
CDR0000415355, U10CA021115, ECOG-E1603
Not Provided
Not Provided
Not Provided
Group Chair, Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Study Chair: David H. Lawson, MD Winship Cancer Institute of Emory University
Investigator: Sanjiv S. Agarwala, MD University of Pittsburgh
Eastern Cooperative Oncology Group
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP